INDEX Trial - This is a National Cancer Research Network (NCRN) multi-centre prospective trial evaluating Focal Therapy using High Intensity Focused Ultrasound for the treatment of localised prostate cancer. Wrexham is the only centre in Wales and North West England, and the trial is also being performed in conjunction with UCLH London, Imperial College Healthcare NHS Trust, Oxford Radcliffe Hospitals NHS Trust, University Hospitals Bristol NHS Foundation Trust and Royal Marsden NHS Foundation Trust.

PROMIS Trial - This is a Medical Research Council (MRC PR11) multi-centre trial investigating the use of multi-parametric Magnetic Resonance Imaging (MP-MRI) as a tool in the diagnosis of prostate cancer. The PROMIS aims to evaluate whether MP-MRI improves the ability to detect as well as rule-out clinically significant prostate cancer in a group of men currently advised to have prostate biopsy. Wrexham is the only centre in Wales and North West England.

SURTIME Trial - This is an EORTC (European Organisation for Research and Treatment of Cancer) randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma. The principal objective of the trial is to investigate whether the sequence of the nephrectomy in patients who receive sunitinib has an effect on patient outcome.

COMPARE Trial - This clinical trial is evaluating patient preferences for the treatment of localised prostate cancer (Comparing treatment options for Prostate cancer).

TISU Trial - NIHR HTA multicentre RCT of shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopy, for ureteric stones. (Therapeutic Interventions for Stones of the Ureter)